HTA280 Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors
Abstract
Authors
Johanna Tasler Josephine Szczesny Janine Leismann Thomas Ecker